Flavopiridol in patients with relapsed or refractory multiple myeloma: A phase 2 trial with clinical and pharmacodynamic end-points

Haematologica

Volumn 91, Issue 3, 2006, Pages 390-393

  Dispenzieri, Angela ^a   Gertz, Morie A ^a   Lacy, Martha Q ^a   Geyer, Susan M ^a   Fitch, Tom R ^b   Fenton, Robert G ^c   Fonseca, Rafael ^b   Isham, Crescent R ^a   Ziesmer, Steven C ^a   Erlichman, Charles ^a   Bible, Keith C ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

Author keywords

Clinical trial; Mcl 1; Therapy

Indexed keywords

CYCLIN D; FLAVOPIRIDOL; PROTEIN BCL 2; PROTEIN MCL 1; PROTEIN P53; RNA POLYMERASE II; STAT3 PROTEIN;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY; DIARRHEA; DRUG ACTIVITY; DRUG EFFECT; DRUG INFUSION; FATIGUE; FEMALE; HUMAN; HUMAN CELL; HYPERCALCEMIA; HYPERGLYCEMIA; HYPOTENSION; IMMUNOBLOTTING; INFECTION; LEUKOPENIA; MALE; MULTIPLE MYELOMA; MYELOMA CELL; NAUSEA; PHASE 2 CLINICAL TRIAL; RELAPSE; THROMBOCYTOPENIA; VOMITING;

AGED; AGED, 80 AND OVER; FEMALE; FLAVONOIDS; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM RECURRENCE, LOCAL; PIPERIDINES; TREATMENT OUTCOME;

EID: 33645393211     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC. Advances in biology of multiple myeloma: clinical applications. Blood 2004;104:607-18.
2. Senderowicz AM. Development of cyclin-dependent kinase modulators as novel therapeutic approaches for hematological malignancies. Leukemia 2001;15:1-9.
3. Kaur G, Stetler-Stevenson M, Sebers S, Worland P, Sedlacek H, Myers C, et al. Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275. J Natl Cancer Inst 1992;84:1736-40.
4. Bible KC, Kaufmann SH. Flavopiridol: a cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells. Cancer Res 1996;56:4856-61.
5. Shapiro GI. Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol. Clin Cancer Res 2004;10:4270S-5S.
6. Kitada S, Zapata JM, Andreeff M, Reed JC. Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. Blood 2000;96:393-7.
7. Bible KC, Bible RH Jr., Kottke TJ, Svingen PA, Xu K, Pang YP, et al. Flavopiridol binds to duplex DNA. Cancer Res 2000;60:2419-28.
8. Lee Y, Kaufmann S, Bible K. Flavopiridol disrupts transcription factor/DNA binding. Proceedings of the American Association for Cancer Research 2001;42:4876a[Abstract].
9. Chao SH, Price DH. Flavopiridol inactivates P-TEFb and blocks most RNA polymerase transcription in vivo. J Biol Chem 2001;276:31793-9.
10. Parker BW, Kaur G, Nieves-Neira W, Taimi M, Kohlhagen G, Shimizu T, et al. Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol. Blood 1998;91:458-65.
11. Schwartz GK, Farsi K, Maslak P, Kelsen DP, Spriggs D. Potentiation of apoptosis by flavopiridol in mitomycin-C-treated gastric and breast cancer cells. Clin Cancer Res 1997;3:1467-72.
12. Akyuz C, Semenov II, Roginskaya VV, Corey S. Flavopiridol-induced growth inhibition and apoptosis of myeloid and myeloma cell lines and blasts. Exp Hematol 2000;28:1497.
13. Gojo I, Zhang B, Fenton RG. The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1. Clin Cancer Res 2002;8:3527-38.
14. Semenov I, Akyuz C, Roginskaya V, Chauhan D, Corey SJ. Growth inhibition and apoptosis of myeloma cells by the CDK inhibitor flavopiridol. Leuk Res 2002;26:271-80.
15. Byrd JC, Peterson BL, Gabrilove J, Odenike OM, Grever MR, Rai K, et al. Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805. Clin Cancer Res 2005;11:4176-81.
16. Arguello F, Alexander M, Sterry JA, Tudor G, Smith EM, Kalavar NT, et al. Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts. Blood 1998;91:2482-90.
17. Patel V, Senderowicz AM, Pinto D Jr, Igishi T, Raffeld M, Quintanilla-Martinez L, et al. Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis. J Clin Invest 1998;102:1674-81.
18. Lam LT, Pickeral OK, Peng AC, Rosenwald A, Hurt EM, Giltnane JM, et al. Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. Genome Biol 2001;2: RESEARCH0041.
19. Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998;102:1115-23.
20. Bible KC, Boerner SA, Kirkland K, Anderl KL, Bartelt D Jr, Svingen PA, et al. Characterization of an ovarian carcinoma cell line resistant to cisplatin and flavopiridol. Clin Cancer Res 2000;6:661-70.